Ibrahim Halil Sahin, Assistant Professor at UPMC Hillman Cancer Center, shared on X:
“The ATOMIC trial is out!
Question becomes what do we do with this data now knowing 100% DFS with two dose of Nivolumab and single dose of ipilumab based on NICHE-2?
Do we even need to chemotherapy ?
Why to use 5FU, a detrimental agent, for highly curable cancer with IO alone?
Additive role of Atezolizumab seems modest, was that right agent ?
So many questions remain unanswered.”
You can find more posts featuring Ibrahim Halil Sahin on OncoDaily.